Quarterly ResultAug 13, 2026, 04:19 PM
Arcadia Biosciences Q2 Net Cash Used $319K; Raises $4M Private Placement
AI Summary
Arcadia Biosciences reported its second quarter and first half 2026 financial results, highlighting a net cash usage of only $319K in Q2 and a cash balance of $4.2 million at quarter-end. The company successfully closed a $4 million private placement in June. While total revenues slightly decreased to $1.443 million in Q2 and $2.543 million in H1, net losses were $6.266 million and $10.651 million respectively, impacted by valuation losses and offering costs. The company emphasized a significant reduction in SG&A expenses and announced plans for new product launches in late 2026 and early 2027.
Key Highlights
- Net cash used in operating activities was $319K in Q2 2026.
- Ended Q2 2026 with $4.2 million in cash and cash equivalents.
- Closed a $4 million private placement in June 2026.
- Total revenues for Q2 2026 were $1.443 million, down 1% YoY.
- Net loss attributable to common stockholders for Q2 2026 was $6.266 million.
- Total revenues for H1 2026 were $2.543 million, down 4% YoY.
- Net loss attributable to common stockholders for H1 2026 was $10.651 million.
- SG&A expenses decreased by $1.0 million in Q2 2026 compared to prior year.
- Plans to launch a new 1-liter espresso in Q4 2026 and three new products in H1 2027.
Price Impact
More from RKDA